

Corresponding author(s):

Double-blind peer review submissions: write DBPR and your manuscript number here instead of author names.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

C	l i
Statistical	l parameters

When statistical analyses are reported	, confirm that the following items are	e present in the relevant	location (e.g. figu	ure legend, tabl	e legend, mair
text, or Methods section).					

n/a	Cor	nfirmed
	\boxtimes	The $\underline{\text{exact sample size}}$ (n) for each experimental group/condition, given as a discrete number and unit of measurement
	\boxtimes	An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	\boxtimes	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes		A description of all covariates tested
	\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	\boxtimes	A full description of the statistics including <u>central tendency</u> (e.g. means) or other basic estimates (e.g. regression coefficient) AND <u>variation</u> (e.g. standard deviation) or associated <u>estimates of uncertainty</u> (e.g. confidence intervals)
	\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
	\boxtimes	Clearly defined error bars State explicitly what error bars represent (e.g. SD, SE, CI)

Our web collection on <u>statistics for biologists</u> may be useful.

Software and code

Policy information about availability of computer code

Data collection

All single cell data were collected using an LSRII flow cytometer (BD Biosciences).

FACS data were analyzed with FlowJoTM 10 software (version 10.2; Treestar, Ashland, OR) using previously published subset definitions (ref. 11). Patterns in the data and differences between groups were analyzed using Prism 7.02 (GraphPad Software).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All data generated and analysed during this study are included in this published article (and its supplementary information files). Two files for source data are

he data that suppor	e contains data underlying Fig 1B through 1F, Fig 2B and supplementary figures 1 to 3. The second file contains uncropped images for Fig 2A. t the findings of this study are available from the corresponding author upon reasonable request.
ield-spe	cific reporting
lease select the bo	est fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences
or a reference copy of t	the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
	nces study design sclose on these points even when the disclosure is negative.
	,
ll studies must dis	No sample size calculation was performed. The background for chimerism and tolerance in our system is essentially zero, any meaningful chimerism is ~1%. Therefore, we estimated that 3 animals per group would be sufficient to see a meaningful difference. Instead we observed
ll studies must dis Sample size	No sample size calculation was performed. The background for chimerism and tolerance in our system is essentially zero, any meaningful chimerism is ~1%. Therefore, we estimated that 3 animals per group would be sufficient to see a meaningful difference. Instead we observed ~20% average chimerism using CD117 immunotoxin conditioning, indicating a very large effect.
ll studies must dis Sample size Data exclusions	No sample size calculation was performed. The background for chimerism and tolerance in our system is essentially zero, any meaningful chimerism is ~1%. Therefore, we estimated that 3 animals per group would be sufficient to see a meaningful difference. Instead we observed ~20% average chimerism using CD117 immunotoxin conditioning, indicating a very large effect. No data were excluded.

Materials & experimental systems		Methods		
n/a	Involved in the study	n/a	Involved in the study	
\boxtimes	Unique biological materials	\boxtimes	ChIP-seq	
	Antibodies		Flow cytometry	
\boxtimes	Eukaryotic cell lines	\boxtimes	MRI-based neuroimaging	
\boxtimes	Palaeontology			
	Animals and other organisms			
\boxtimes	Human research participants			

Antibodies

Antibodies used

For CD117 immunotoxin construction & HSC depletion:

Marker Color Clone # Vendor Cat# Lot#

c-kit/CD117 biotin 2B8 Biolegend 105804 170777-31

For transient immunosuppression:

Marker Color Clone # Vendor Cat# Lot# CD4 YTS177 Bioxcell BE0003-3 669218M1

CD8 YTS169 Bioxcell BE0117 650018F1

CD40L MR-1 Bioxcell BE0017-1 627317J2

For FACS analysis:

Marker Color Clone # Vendor Cat# Lot# H2Kd FITC SF1-1.1 Biolegend 116606 B175000 Ter119 AF700 Ter-119 Biolegend 116210 B247524 CD11b APC M1/70 Biolegend 101212 B261578 Gr-1 PE/Cy7 RB6-8C5 Biolegend 108416 B248638 CD19 APC/Cy7 6D5 Biolegend 115530 B228154 CD3 PB 17A2 Biolegend 100214 B227246 CD49b(PAN-NK) PE DX5 Biolegend 108908 B223922 Sca1 APC/Cy7 D7 Biolegend 108126 B227481

Flt3/CD135 APC A2F10 Biolegend 135312 B209576

IL7ra BV 605 A7R34 Biolegend 135041 B225950 c-kit/CD117 APC 2B8 Biolegend 105812 B217855 Lin PB Biolegend 133310 B225582 CD150 PE/Cy7 TC15-12F12.2 Biolegend 115914 B210492 CD34 biotin RAM34 BD 13-0341-85 E02498-1632

For HSC depletion:

Marker Color Clone # Vendor Cat# Lot# c-kit/CD117 N/A ACK2 Biolegend 135101 N/A

Validation

For anti-CD117/ckit: reported in vivo transient removal of >98% of endogenous HSCs in immunodeficient mice; Science 318(5854): 1296-1299

The following validations are stated by the vendor:

For anti-CD4/YTS177: reported in vivo blockade of CD4+ T cell response; Tanspl Immunol 33(2): 125-129

For anti-CD8/YTS169: reported in vivo CD8+ T cell depletion; Nature 521 (7550):99-104

For anti-CD40L/MR-1: reported in vivo blockade of CD40/CD40L signaling; Nature Commun 6:7566

Validation statement of FACS Ab vendor:

Each lot of each antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. Detailed information is available at the links below:

Marker Color Clone # Source Link

H2Kd FITC SF1-1.1 Ms http://www.biolegend.com/fitc-anti-mouse-h-2kd-antibody-1860.html

Ter119 AF700 Ter-119 Rat https://www.biolegend.com/en-us/search-results/alexa-fluor-700-anti-mouse-ter-119-erythroid-cellsantibody-3428

CD11b APC M1/70 Rat http://www.biolegend.com/apc-anti-mouse-human-cd11b-antibody-345.html Gr-1 PE/Cy7 RB6-8C5 Rat http://www.biolegend.com/pe-cy7-anti-mouse-ly-6g-ly-6c-gr-1-antibody-1931.html CD19 APC/Cy7 6D5 Rat http://www.biolegend.com/apc-cy7-anti-mouse-cd19-antibody-3903.html

CD3 PB 17A2 Rat http://www.biolegend.com/pacific-blue-anti-mouse-cd3-antibody-3317.html

CD49b(PAN-NK) PE DX5 Rat http://www.biolegend.com/pe-anti-mouse-cd49b-pan-nk-cells-antibody-234.html Sca1 APC/Cy7 D7 Rat http://www.biolegend.com/apc-cy7-anti-mouse-ly-6a-e-sca-1-antibody-6752.html

Flt3/CD135 APC A2F10 Rat https://www.biolegend.com/en-us/products/apc-anti-mouse-cd135-antibody-6284

IL7ra BV 605 A7R34 Rat http://www.biolegend.com/brilliant-violet-605-anti-mouse-cd127-il-7ralpha-antibody-8539.html

c-kit/CD117 APC 2B8 Rat https://www.biolegend.com/en-us/search-results/brilliant-violet-711-anti-mouse-cd117-c-kitantibody-12049

Lin PB Rat http://www.biolegend.com/pacific-blue-anti-mouse-lineage-antibody-cocktail-7765.html CD150 PE/Cy7 TC15-12F12.2 Rat http://www.biolegend.com/pe-cy7-anti-mouse-cd150-slam-antibody-3056.html CD34 biotin RAM34 Rat http://www.bdbiosciences.com/us/applications/research/stem-cell-research/cancer-research/mouse/ pe-rat-anti-mouse-cd34-ram34/p/551387

c-kit/CD117 biotin 2B8 & Rat https://www.biolegend.com/en-us/products/biotin-anti-mouse-cd117-c-kit-antibody-73 c-kit/CD117 N/A ACK2 Rat https://www.biolegend.com/en-us/products/purified-anti-mouse-cd117-c-kit-antibody-6140

Animals and other organisms

Policy	information about	studies involving	g animals;	ARRIVE	guidelines	recommended	for re	porting	ganimal	research
--------	-------------------	-------------------	------------	--------	------------	-------------	--------	---------	---------	----------

Mus musculus; males; C57BI/6, Balb/c and CBA/Ca; 8-12 weeks of age at time of bone marrow transplantation Laboratory animals

Wild animals n/a

Field-collected samples n/a

Flow Cytometry

Plots

Confirm that:

The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

 $\boxed{\hspace{-0.2cm} \diagup}$ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Leukocytes were isolated from the blood, thymus, spleen, lymph node, BM, liver and lung from mice that had received BM transplantation. After lysing red blood cells, the cells were washed and incubated for 20 min with Fc blocking antibody (Clone 93, 1:50 BioLegend, San Diego, CA) followed by the relevant antibody combinations (1:50 dilution) and FACS staining buffer for 30 min at 4°C.

Instrument	All data were collected using an LSRII flow cytometer (BD Biosciences)
Software	All data were analyzed with FlowJoTM 10 software (version 10.2; Treestar, Ashland, OR).
Cell population abundance	n/a: Leukocytes were not sorted.
Gating strategy	Details of gating strategy is shown in the figures of supplementary information.

 $\[\]$ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.